MedTrace Logo

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

NCT06080698 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1030

Last updated 2026-03-11

No results posted yet for this study

Summary

The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.

Conditions

  • Gram-negative Bacteremia

Interventions

DRUG

Intravenous Antibiotics

Participants will continue to receive intravenous antibiotics until the completion of the treatment course

DRUG

Oral Antibiotics

Participants will transition to oral antibiotics at the time of randomization and will continue oral antibiotics until the completion of the treatment course

Sponsors & Collaborators

Principal Investigators

  • Pranita D Tamma, MD, MHS · Children's Hospital of Philadelphia

  • Sara E Cosgrove, MD, MS · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-22
Primary Completion
2027-05-31
Completion
2027-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06080698 on ClinicalTrials.gov